Higher C-reactive protein and soluble tumor necrosis factor receptor levels are associated with poor physical function and disability: A cross-sectional analysis of a cohort of late middle-aged african Americans

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 65 A, Issue 3, 2010, Pages 274-281

  Haren, Matthew T ^a,b,c   Malmstrom, Theodore K ^a   Miller, Douglas K ^d   Patrick, Ping ^a   Perry, H M ^b   Herning, Margaret M ^e   Banks, William A ^a,b   Morley, John E ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d INDIANA UNIVERSITY CENTER FOR AGING RESEARCH   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Aging; Cytokine receptors; Disability

Indexed keywords

C REACTIVE PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

AFRICAN AMERICAN; AGE; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISABLED PERSON; ETHNOLOGY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; PHYSIOLOGY; RETROSPECTIVE STUDY; UNITED STATES; URBAN POPULATION;

AFRICAN AMERICANS; AGE FACTORS; AGED; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DISABLED PERSONS; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MISSOURI; MOTOR ACTIVITY; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; URBAN POPULATION;

EID: 77949512764     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glp148     Document Type: Article

References (47)

1. Miller DK, Malmstrom TK, Joshi S, Andresen EM, Morley JE, Wolinsky FD. Clinically relevant levels of depressive symptoms in community-dwelling middle-aged African Americans. J Am Geriatr Soc. 2004;52(5):741-748.
2. Wolinsky FD, Miller DK, Andresen EM, Malmstrom TK, Miller JP. Health-related quality of life in middle-aged African Americans. J Gerontol B Psychol Sci Soc Sci. 2004;59(2):S118-S123.
3. Miller DK, Wolinsky FD, Malmstrom TK, Andresen EM, Miller JP. Inner city, middle-aged African Americans have excess frank and subclinical disability. J Gerontol A Biol Sci Med Sci. 2005;60(2):207-212.
4. Toth MJ, Ades PA, Tischler MD, Tracy RP, LeWinter MM. Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure. Int J Cardiol. 2006;109(2):179-187.
5. Unden AL, Andreasson A, Elofsson S, et al. Inflammatory cytokines, behaviour and age as determinants of self-rated health in women. Clin Sci (Lond). 2007;112(6):363-373.
6. Duncan BB, Schmidt MI, Pankow JS, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004;53(9):2473-2478.
7. Ferris WF, Naran NH, Crowther NJ, Rheeder P, van der Merwe L, Chetty N. The relationship between insulin sensitivity and serum adiponectin levels in three population groups. Horm Metab Res. 2005;37(11):695-701.
8. Rolland YM, Haren MT, Patrick P, et al. Adiponectin levels in obese and non-obese middle-aged African-American women. Obes Res Clin Pract. 2007;1(1):27-37.
9. Dibbs Z, Thornby J, White BG, Mann DL. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol. 1999;33(7):1935-1942.
10. Peters M, Jacobs S, Ehlers M, et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med. 1996;183(4):1399-1406.
11. Dziedzic T, Gryz EA, Turaj W, Slowik A, Szczudlik A. Serum interleukin-6 soluble receptor in relation to interleukin-6 in stroke patients. J Mol Neurosci. 2004;24(2):293-298. (Pubitemid 41359156)
12. Novick D, Shulman LM, Chen L, Revel M. Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody. Cytokine. 1992;4(1):6-11.
13. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83(1):113-118.
14. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151(3):1548-1561.
15. Data File Documentation, National Health Interview Second Supplement on Aging (machine readable data file and documentation). In: Statistics NCfH, ed. Hyattsville, MD: National Center for Health Statistics, 1994.
16. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179-186.
17. Nagi SZ. An epidemiology of disability among adults in the United States. Milbank Mem Fund Q Health Soc. 1976;54(4):439-467.
18. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85-M94.
19. Miller D, Wolinsky F, Andresen E. Adverse outcomes and correlates of change in the short physical performance battery over 36 months in the African American Health project. J Gerontol A Biol Sci Med Sci. 2008;63(5):487-494.
20. Ling SM, Simonsick EM, Ferrucci L. A painful interface between normal aging and disease. J Gerontol A Biol Sci Med Sci. 2007;62(6):613-615.
21. Morley JE, Perry HM, III, Miller DK. Editorial: something about frailty. J Gerontol A Biol Sci Med Sci. 2002;57(11):M698-M704.
22. Kuo HK, Bean JF, Yen CJ, Leveille SG. Linking C-reactive protein to late-life disability in the National Health and Nutrition Examination Survey (NHANES) 1999-2002. J Gerontol A Biol Sci Med Sci. 2006;61(4):380-387.
23. Aiello AE, Haan MN, Pierce CM, Simanek AM, Liang J. Persistent infection, inflammation, and functional impairment in older Latinos. J Gerontol A Biol Sci Med Sci. 2008;63(6):610-618.
24. Leng SX, Xue QL, Tian J, Walston JD, Fried LP. Inflammation and frailty in older women. J Am Geriatr Soc. 2007;55(6):864-871.
25. Skoog T, Dichtl W, Boquist S, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J. 2002;23(5):376-383.
26. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101(18):2149-2153.
27. Baugh JA, Bucala R. Mechanisms for modulating TNF alpha in immune and inflammatory disease. Curr Opin Drug Discov Devel. 2001;4(5):635-650.
28. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis. 2003;62(suppl 2):ii2-ii9.
29. Kroeger KM, Carville KS, Abraham LJ. The-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34(5):391-399.
30. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94(7):3195-3199.
31. Lakka HM, Lakka TA, Rankinen T, et al. The TNF-alpha G-308A polymorphism is associated with C-reactive protein levels: the HERITAGEFamily Study. Vascul Pharmacol. 2006;44(5):377-383.
32. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-1143.
33. McDermott MM, Guralnik JM, Corsi A, et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J. 2005;150(2):276-281.
34. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53(3):693-700. (Pubitemid 38270639)
35. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation. Relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke. 2007;38(4):1229-1237.
36. Schlager O, Exner M, Mlekusch W, et al. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis. Stroke. 2007;38(4):1263-1268.
37. Ishikawa S, Kayaba K, Gotoh T, Nakamura Y, Kajii E. Metabolic syndrome and C-reactive protein in the general population: JMS Cohort Study. Circ J. 2007;71(1):26-31.
38. Yang SP, Gong CX, Cao BY, Yan C. Relationship between serum high-sensitivity C-reactive protein and obesity and impaired glycose metabolism in children and adolescents. Zhonghua Er Ke Za Zhi. 2006;44(12):933-936.
39. Toth MJ, Matthews DE, Tracy RP, Previs MJ. Age-related differences in skeletal muscle protein synthesis: relation to markers of immune activation. Am J Physiol Endocrinol Metab. 2005;288(5):E883-E891.
40. Thissen JP. How proinflammatory cytokines may impair growth and cause muscle wasting. Horm Res. 2007;67(suppl 1):64-70.
41. Phillips T, Leeuwenburgh C. Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction. FASEB J. 2005;19(6):668-670.
42. Chevrel G, Granet C, Miossec P. Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis. 2005;64(9):1257-1262.
43. Tisdale MJ. The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol. 2005;3(3):209-217.
44. Spate U, Schulze PC. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004;7(3):265-269.
45. Langen RC, Van Der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J. 2004;18(2):227-237.
46. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS, Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000;289(5488):2363-2366.
47. Li YP, Reid MB. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol. 2000;279(4):R1165-R1170.